Physician profile
Robert K White
NPI 1740208834
$8,577.10
in general payments reported to CMS, 2019-2025
43 companies · $1,333 in 2025
The $1,333 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $1,075 · 2021: $1,433 · 2022: $1,415 · 2023: $1,160 · 2024: $1,419 · 2025: $1,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,912.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,380.87 | 2019-2025 | Rinvoq, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $999.31 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $863.69 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $812.89 | 2019-2025 | Repatha, Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $551.19 | 2019-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $457.23 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Lilly USA, LLC | $411.89 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $383.25 | 2022-2025 | |
| Glaxosmithkline, LLC. | $306.56 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $298.01 | 2024-2025 | Caplyta |
| Pfizer INC. | $228.47 | 2020-2025 | |
| Avanir Pharmaceuticals, INC. | $227.48 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $211.19 | 2019-2024 | Xarelto |
| Arbor Pharmaceuticals, INC. | $158.49 | 2020-2022 | |
| Allergan, INC. | $126.35 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.